GlassScriptPhysician profile
Michelle E Kubik
NPI 1518337393
$2,296.01
in general payments reported to CMS, 2019-2025
14 companies · $440 in 2025
The $440 reported for 2025 was more than what a typical Physician Assistant provider received nationally (typical 2025 total: $183).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $277 · 2022: $498 · 2023: $563 · 2024: $518 · 2025: $440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,521.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,520.96 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,201.04 | 2021-2025 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $184.03 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $173.97 | 2023-2025 | Auvelity |
| Novo Nordisk INC | $128.19 | 2021-2023 | Wegovy |
| Tris Pharma INC | $125.55 | 2024-2025 | Dyanavel Xr |
| Biohaven Pharmaceutical Holding Company LTD. | $123.43 | 2022 | |
| Inspire Medical Systems, INC. | $90.57 | 2024 | Inspire |
| Neurocrine Biosciences, INC. | $72.84 | 2023-2024 | Ingrezza |
| Idorsia Pharmaceuticals US INC | $48.10 | 2023 | Quviviq |
| Lundbeck LLC | $41.96 | 2022-2023 | Rexulti |
| Vanda Pharmaceuticals INC. | $34.25 | 2025 | Fanapt |
| Takeda Pharmaceuticals U.S.A., INC. | $31.72 | 2022-2024 | Trintellix |
| Janssen Pharmaceuticals, INC | $21.22 | 2024 | Spravato |
| Almatica Pharma LLC | $19.14 | 2025 | Loreev Xr |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michelle Kubik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.